Division of Bio-Medical Informatics, Indian Council of Medical Research, New Delhi, India.
Clinton Health Access Initiative, India Office, All India Institute of Medical Sciences, New Delhi, India.
Indian J Med Res. 2022 May-Jun;155(5&6):513-517. doi: 10.4103/ijmr.ijmr_3500_21.
COVID-19 was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. Since then, efforts were initiated to develop safe and effective vaccines. Till date, 11 vaccines have been included in the WHO's emergency use list. The emergence and spread of variant strains of SARS-CoV-2 has altered the disease transmission dynamics, thus creating a need for continuously monitoring the real-world effectiveness of various vaccines and assessing their overall impact on disease control. To achieve this goal, the Indian Council of Medical Research (ICMR) along with the Ministry of Health and Family Welfare, Government of India, took the lead to develop the India COVID-19 Vaccination Tracker by synergizing three different public health databases: National COVID-19 testing database, CoWIN vaccination database and the COVID-19 India portal. A Vaccine Data Analytics Committee (VDAC) was constituted to advise on various modalities of the proposed tracker. The VDAC reviewed the data related to COVID-19 testing, vaccination and patient outcomes available in the three databases and selected relevant data points for inclusion in the tracker, following which databases were integrated, using common identifiers, wherever feasible. Multiple data filters were applied to retrieve information of all individuals ≥18 yr who died after the acquisition of COVID-19 infection with or without vaccination, irrespective of the time between vaccination and test positivity. Vaccine effectiveness (VE) against the reduction of mortality and hospitalizations was initially assessed. As compared to the hospitalization data, mortality reporting was found to be much better in terms of correctness and completeness. Therefore, hospitalization data were not considered for analysis and presentation in the vaccine tracker. The vaccine tracker thus depicts VE against mortality, calculated by a cohort approach using person-time analysis. Incidence of COVID-19 deaths among one- and two-dose vaccine recipients was compared with that among unvaccinated groups, to estimate the rate ratios (RRs). VE was estimated as 96.6 and 97.5 per cent, with one and two doses of the vaccines, respectively, during the period of reporting. The India COVID-19 Vaccination Tracker was officially launched on September 9, 2021. The high VE against mortality, as demonstrated by the tracker, has helped aid in allaying vaccine hesitancy, augmenting and maintaining the momentum of India's COVID-19 vaccination drive.
2020 年 3 月 11 日,世界卫生组织(WHO)宣布 COVID-19 为大流行。此后,人们开始努力开发安全有效的疫苗。迄今为止,已有 11 种疫苗被列入世卫组织的紧急使用清单。SARS-CoV-2 变异株的出现和传播改变了疾病传播动态,因此需要不断监测各种疫苗的真实世界效果,并评估它们对疾病控制的总体影响。为了实现这一目标,印度医学研究理事会(ICMR)与印度政府的卫生和家庭福利部合作,通过整合三个不同的公共卫生数据库:国家 COVID-19 检测数据库、CoWIN 疫苗接种数据库和 COVID-19 印度门户,率先开发了印度 COVID-19 疫苗接种追踪器。成立了疫苗数据分析委员会(VDAC),就拟议追踪器的各种模式提供咨询。VDAC 审查了三个数据库中与 COVID-19 检测、疫苗接种和患者结果相关的数据,并选择了相关数据点纳入追踪器,然后尽可能使用通用标识符整合数据库。应用了多个数据筛选器来检索感染 COVID-19 后无论是否接种疫苗,在获得 COVID-19 感染后≥18 岁的所有个体的死亡信息,无论接种疫苗和检测阳性之间的时间间隔如何。最初评估了疫苗对死亡率和住院率降低的有效性。与住院数据相比,死亡率报告在准确性和完整性方面要好得多。因此,未考虑将住院数据纳入疫苗追踪器进行分析和展示。疫苗追踪器因此描绘了使用人员时间分析的队列方法计算的死亡率降低的疫苗有效性。比较了一剂和两剂疫苗接种者与未接种疫苗者的 COVID-19 死亡发生率,以估计比率比(RR)。报告期间,一剂和两剂疫苗的疫苗有效性分别估计为 96.6%和 97.5%。2021 年 9 月 9 日,印度 COVID-19 疫苗接种追踪器正式推出。追踪器显示的高死亡率疫苗有效性有助于缓解疫苗犹豫情绪,增强和维持印度 COVID-19 疫苗接种运动的势头。